Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Overview of Cutera Inc
Cutera Inc is a pioneering company in laser technology and medical aesthetics that designs, develops, manufactures, markets, and services a comprehensive range of energy-based medical aesthetic systems. Renowned for its advanced ND:YAG technology, Cutera offers safe and effective treatment solutions that are used by medical professionals globally to address a variety of aesthetic concerns including skin resurfacing, acne treatment, body contouring, and hair removal. The company has earned a reputation as a trusted authority in the aesthetic device industry by consistently delivering state-of-the-art products that integrate innovation, sophistication, and performance.
Innovative Technology and Product Portfolio
Cutera's success is built upon its commitment to advancing laser and optical engineering. At its core, the company develops high-performance devices that harness energy to produce precise outcomes for various medical aesthetic procedures. Its portfolio includes a collection of premium products designed around the needs of the medical aesthetic community, enabling clinicians to deliver faster and safer procedures. With a focus on energy-based modalities, Cutera champions breakthrough technologies that combine picosecond, nanosecond, and dual-wavelength systems to enhance safety and efficacy in treatments.
Business Model and Market Presence
The company primarily derives its revenue through the direct sale and servicing of its innovative devices, backed by a strong network of operations in North America and multiple key international markets. Cutera maintains a significant market presence by continually updating its product offerings to match evolving clinical needs, and by keeping its focus on regulatory compliance and performance excellence. Its operations are built on a model that emphasizes customer support, ongoing clinical education, and product reliability, ensuring practitioners can trust the devices’ performance on a global scale.
Operational Excellence and Industry Position
Cutera sets itself apart by not only offering cutting-edge technology but also instilling confidence in practitioners through balanced design and effective usability. The company focuses on developing solutions that ensure better results through carefully designed energy-based systems. This process is supported by a deep understanding of anatomical nuances and treatment protocols, making its products highly adaptable across various clinical applications. Such operational excellence positions Cutera as an integral player in the medical aesthetics landscape, where it continues to meet the sophisticated demands of both clinicians and patients.
Commitment to Safety and Efficacy
Safety and efficacy remain central to the design of Cutera's devices, which are engineered to deliver predictable outcomes while minimizing risks. The company adheres to strict quality standards and regulatory guidelines, ensuring that every system functions reliably across diverse clinical scenarios. This focus on patient safety and treatment effectiveness is fundamental to its reputation and long-standing trust among practitioners globally.
Comprehensive Support and Market Adaptation
Understanding that innovation alone does not define success, Cutera also invests in comprehensive support systems, ensuring that medical professionals receive continuous training and technical assistance. This approach helps maximize the performance of their devices in clinical settings, thereby reinforcing their commitment to ongoing product development and customer-centric solutions. The company's ability to adapt its product strategies in response to market feedback underlines its expertise and dedication to meeting the evolving needs of the medical aesthetics industry.
Global Influence and Industry Expertise
With direct operations in numerous countries, Cutera leverages its global footprint to steer advancements in the energy-based aesthetics arena. Its international presence not only broadens its market reach but also enhances its capacity for cross-border innovation, enriching the experience and expertise shared within the medical aesthetics community. In doing so, the company provides valuable insights into best practices, industry trends, and technological progress, fostering a collaborative environment that benefits practitioners and patients alike.
Cutera, Inc. (CUTR) announced its response to a recent FDA inquiry regarding marketing materials related to its MyJuliet device. The company had previously removed all materials related to gynecological uses in 2019. However, a vestigial marketing piece was recently identified in an FDA Warning Letter, attributed to a third-party website that Cutera managed. Cutera is taking corrective actions to ensure compliance and has not promoted MyJuliet since 2019, with minimal sales. The company intends to exit this market segment while supporting its customers and complying with FDA guidance.
Cutera, Inc. (CUTR), a prominent provider of aesthetic and dermatology solutions, announced that CEO Dave Mowry and VP Greg Barker will speak at the Piper Sandler 34th Annual Healthcare Conference. The event is scheduled for November 30, 2022, at 2:00 PM ET, and will take place at the Lotte New York Palace Hotel in New York, NY. The session will also be available via webcast on Cutera's website, with a replay provided approximately one hour after the event concludes.
Cutera, Inc. (NASDAQ: CUTR) announced participation in a fireside chat at the Stephens Annual Investment Conference. CEO Dave Mowry and VP Greg Barker will speak on November 16, 2022, at 4:00 pm CT in Nashville, TN. Interested parties can access the live webcast through the Investor Relations section of Cutera's website, with a replay available one hour after the event concludes.
Based in Brisbane, California, Cutera specializes in aesthetic and dermatology solutions, providing innovative products since 1998.
Cutera, Inc. (CUTR) will participate in a fireside chat at the Stifel Healthcare Conference on November 15, 2022, at 8:00 am ET. The event will feature CEO Dave Mowry and Executive Chairperson J. Daniel Plants, providing insights into the company's aesthetic and dermatology solutions. Attendees can access the live webcast via Cutera's Investor Relations page, with a replay available one hour post-event. Headquartered in Brisbane, California, Cutera has been a leader in innovative dermatological products since 1998.
Cutera, Inc. (NASDAQ: CUTR) announces the extensive launch of AviClear, the first FDA-cleared and Health Canada-approved device for treating acne. The product has gained significant traction since its FDA clearance in March 2022, receiving the 'Best Laser Treatment for Acne' award from Cosmopolitan Magazine. A new financing option is available for US consumers starting at $99/month. CEO Dave Mowry expressed confidence in growing patient demand, aiming to establish AviClear as the gold standard in acne treatment.
Cutera, Inc. (Nasdaq: CUTR) reported Q3 2022 revenue of $62.8 million, marking a 9% year-over-year increase. Capital equipment sales grew 27%, while consumable product revenue surged 66%. Despite a GAAP net loss of $12.1 million, the company reiterated its 2022 revenue guidance of $255 million to $260 million, driven by strong demand for its products and a full launch of AviClear in North America. The company faced foreign exchange headwinds of approximately $17 million but expects constant currency growth of 18-20% for the year.
Cutera, Inc. (CUTR) presented positive 12-month clinical data for AviClear at the Annual Fall Clinical Dermatology Conference held from October 20-23 in Las Vegas. The data indicates that after three treatment sessions, 92% of patients experienced visible improvement in acne after 12 months. Additionally, three-fourths of participants showed significant improvement, and two-thirds were assessed as clear or almost-clear. AviClear, the only FDA-cleared device for acne treatment, aims to provide an alternative to isotretinoin. The findings support the device's long-term effectiveness and safety.
Cutera, Inc. (CUTR) will announce its Q3 2022 financial results on November 3, 2022, after market close, followed by a conference call at 1:30 p.m. PT (4:30 p.m. ET). Interested parties can join the call by calling 1-800-319-4610 domestically or +1-631-891-4304 internationally, or via webcast on their website. Cutera specializes in aesthetic and dermatology solutions since 1998, providing innovative and effective treatment options worldwide.
Cutera, Inc. (CUTR) reports significant adoption of its AviClear laser treatment, with over 1,000 procedures performed since its launch in April 2022. This device is the first FDA-cleared option for treating all severities of acne. Recently, AviClear also gained approval from Health Canada. About 90% of patients showed visible improvement after treatment, scoring 4.9 out of 5 for satisfaction. CEO David Mowry noted unprecedented speed in physician adoption and patient interest, underscoring AviClear's impact in modern skincare.
Argo Group International Holdings, Ltd. announced the appointment of
FAQ
What is the current stock price of Cutera (CUTR)?
What is the market cap of Cutera (CUTR)?
What is Cutera Inc's core business?
What type of technology does Cutera specialize in?
How does Cutera generate revenue?
What are the key clinical applications of Cutera's products?
How does Cutera ensure patient safety and treatment efficacy?
What distinguishes Cutera from its competitors?
In which markets does Cutera operate?
How does Cutera support the medical aesthetic community?
